Skip to main content
. Author manuscript; available in PMC: 2022 Apr 7.
Published in final edited form as: Adv Exp Med Biol. 2021;1322:115–138. doi: 10.1007/978-981-16-0267-2_5

Table 5.1.

Antivirals approved for chronic hepatitis B

Drug Route Class HBV DNA EC50, μM Company FDA approval year
Lamivudine Oral Nucleoside analog 0.56 [21] GlaxoSmithKline 1998
Adefovir dipivoxil Oral Nucleotide analog 0.58 [21] Gilead Sciences 2002
Entecavir Oral Nucleoside analog 0.00036 [21] BMS 2005
Tenofovir disoproxil fumarate Oral Nucleotide analog 0.1 [22] Gilead Sciences 2008
Telbivudine Oral Nucleoside analog 1.3 [23] Novartis 2006
Tenofovir alafenamide Oral Nucleotide analog 0.0347 [24] Gilead Sciences 2016
Interferon alpha 2b Parenteral Immunomodulator Merck 1991
Peginterferon alpha 2a Parenteral Immunomodulator Genentech 2005
Clevudine Oral Nucleoside analog 0.053 [21] Bukwang/Esai Pharmaceuticals 2009
Besifovir (LB80380) Oral Nucleotide analog 0.5 [25] LG Chem Ltd. n/a
Thymosin alpha-1 Parenteral Immunomodulator SciClone Pharmaceuticals

EC50 median effective concentration to inhibit HBV DNA replication, n/a not applicable